✦ LIBER ✦

2.209 Long-term double-blind, placebo-controlled evaluation of the safety and efficacy of safinamide as an add-on to stable dopamine agonist therapy in patients with Parkinson's disease

✍ Scribed by R. Anand; V. Lucini; R. Guiliani; S. Rossetti

Book ID: 117752860
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 68 KB
Volume: 13
Category: Article
ISSN: 1353-8020
DOI: 10.1016/s1353-8020(08)70620-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to

A double-blind, placebo-controlled evalu

A double-blind, placebo-controlled evaluation of the efficacy and safety of loreclezole as add-on therapy in patients with uncontrolled partial seizures

✍ T Rentmeester; A Janssen; J Hulsman; F Scholtes; B van der Kleij; J Overweg; J M 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 655 KB

Sixty-two patients with uncontrolled partial seizures participated in a 12-week, double-blind, placebo-controlled add-on-trial. Thirty-two patients received loreclezole and 30 a placebo as add-on therapy. Loreclezole was targeted at a plasma level of 1-2 mg/l. In spite of an antiepileptic therapy, u

Safety and efficacy of linagliptin as ad

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

✍ M.-R. Taskinen; J. Rosenstock; I. Tamminen; R. Kubiak; S. Patel; K. A. Dugi; H.- 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 797 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE)

✍ Ik-Kyung Jang; Neil J. Weissman; Michael H. Picard; Michael R. Zile; Veronica Pe 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 264 KB

A Randomized, Double-Blind, Placebo-Cont

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous MCC-135 as an Adjunct to Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: Rationale and Design of the Evaluation of MCC-135 for Left Ventricular Salvage in Acute MI (EVOLVE) Study

✍ Ik-Kyung Jang; Veronica Pettigrew; Michael H. Picard; Peter R. Kowey; Valentin D 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 219 KB